D-Index & Metrics Best Publications

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 89 Citations 32,077 484 World Ranking 7937 National Ranking 4269

Overview

What is he best known for?

The fields of study Christopher J. Logothetis is best known for:

Prostate cancer
Cancer
Prostate-specific antigen

In his articles, Christopher J. Logothetis combines various disciplines, including Oncology and Gastroenterology. He undertakes multidisciplinary studies into Gastroenterology and Urology in his work. In his works, he conducts interdisciplinary research on Urology and Oncology. He incorporates Prostate cancer and Docetaxel in his research. He connects Docetaxel with Cancer in his study. Christopher J. Logothetis performs multidisciplinary study in the fields of Cancer and Cancer research via his papers. Christopher J. Logothetis integrates many fields in his works, including Cancer research and Prostate cancer. As part of his studies on Internal medicine, he frequently links adjacent subjects like Bone remodeling. Christopher J. Logothetis combines topics linked to LNCaP with his work on Prostate.

His most cited work include:

Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties (60 citations)
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. (34 citations)
Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials (33 citations)

What are the main themes of his work throughout his whole career to date

His study in Androgen receptor extends to Internal medicine with its themes. He integrates Cancer and Regimen in his research. He regularly ties together related areas like Internal medicine in his Regimen studies. He performs multidisciplinary study in Prostate cancer and Prostate in his work. Christopher J. Logothetis integrates Prostate with Prostate cancer in his study. He carries out multidisciplinary research, doing studies in Oncology and Cancer research. He integrates several fields in his works, including Cancer research and Cancer. His work often combines Urology and Dermatology studies. Christopher J. Logothetis performs multidisciplinary study in the fields of Dermatology and Gastroenterology via his papers.

Christopher J. Logothetis most often published in these fields:

Internal medicine (94.12%)
Cancer (88.24%)
Prostate cancer (82.35%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina.
The New England Journal of Medicine (2013)

2811 Citations

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse;Jaeil Ahn;Rehan Akbani;Adrian Ally.
Cell (2015)

1968 Citations

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi.
Lancet Oncology (2014)

1592 Citations

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis.
Lancet Oncology (2012)

1030 Citations

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano.
Journal of Clinical Oncology (2016)

919 Citations

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad.
Lancet Oncology (2015)

879 Citations

Steps toward mapping the human vasculature by phage display

Wadih Arap;Mikhail G. Kolonin;Martin Trepel;Johanna Lahdenranta.
Nature Medicine (2002)

747 Citations

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

Christopher J. Logothetis;Francisco H. Dexeus;Laury Finn;Avishay Sella.
Journal of Clinical Oncology (1990)

744 Citations

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi.
Journal of Clinical Oncology (2017)

645 Citations

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao.
Cancer Cell (2018)

562 Citations

If you think any of the details on this page are incorrect, let us know.